Authorized purpose: Provide notification-only parallel workflow triage of adult non-contrast brain CT studies acquired in the acute setting within 24 hours of symptom onset or since last known well when onset is unclear, notifying a specialist when intracranial hemorrhage is suspected.
Clinical role
Parallel, notification-only study triage that recommends specialist review without removing or deprioritizing cases from the standard worklist.
Images and patients
CT/CTA · Brain
Key limitation
Keep in mind: Not for mobile diagnostic use, isolated subarachnoid hemorrhage, recent neurosurgery or endovascular neurointervention within 6 weeks, or prior intracranial hemorrhage within 4 weeks. Not suitable for scan data with tumors or abscesses, coils, shunts, embolization, movement artifacts, or specified intracranial vascular pathologies. Results do not replace full patient evaluation or diagnosis.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Provide notification-only parallel workflow triage of adult non-contrast brain CT studies acquired in the acute setting within 24 hours of symptom onset or since last known well when onset is unclear, notifying a specialist when intracranial hemorrhage is suspected.
Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Brain Input: Non-contrast brain CT images from adult acute-care patients within 24 hours of acute-symptom onset or since last known well when unclear; the FDA packet states validation and intended use on GE and Philips scanners.
Who uses it?Intended users: Hospital networks and trained clinicians, including neurovascular or neurosurgical specialists who receive and review the notification.
What does the software produce?Output: Priority notification or a suspected-hemorrhage flag to clinicians, accessible through a web interface and mobile application, with compressed preview images for informational notification only; notified clinicians must view non-compressed images on a diagnostic viewer.
What is its most important limitation?Key limitation: Not for mobile diagnostic use, isolated subarachnoid hemorrhage, recent neurosurgery or endovascular neurointervention within 6 weeks, or prior intracranial hemorrhage within 4 weeks. Not suitable for scan data with tumors or abscesses, coils, shunts, embolization, movement artifacts, or specified intracranial vascular pathologies. Results do not replace full patient evaluation or diagnosis.
Clinical takeaway. Clinical role: Provide notification-only parallel workflow triage of adult non-contrast brain CT studies acquired in the acute setting within 24 hours of symptom onset or since last known well when onset is unclear, notifying a specialist when intracranial hemorrhage is suspected.
Evidence takeaway. Evidence from the reviewed source record: Retrospective standalone testing used 341 non-contrast CT studies from 30 U.S. hospitals and clinics; all cases were processed. Ground truth used experienced U.S. board-certified neuroradiologists. The confusion matrix was TP 149, TN 159, FP 15, FN 18, yielding overall sensitivity (positive percentage agreement) 89.22% and specificity (negative percentage agreement) 91.37%. Subgroup endpoints include ICH subtype, gender, age, slice thickness, site, and hemorrhage volume. A separate time-to-notification analysis reported 50-126 seconds; the FDA primary acceptance criterion was 80% sensitivity and specificity.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Provide notification-only parallel workflow triage of adult non-contrast brain CT studies acquired in the acute setting within 24 hours of symptom onset or since last known well when onset is unclear, notifying a specialist when intracranial hemorrhage is suspected.
Non-contrast brain CT images from adult acute-care patients within 24 hours of acute-symptom onset or since last known well when unclear; the FDA packet states validation and intended use on GE and Philips scanners.
Priority notification or a suspected-hemorrhage flag to clinicians, accessible through a web interface and mobile application, with compressed preview images for informational notification only; notified clinicians must view non-compressed images on a diagnostic viewer.
Hospital/clinical acute-care environment and existing patient pathways; adult acute cases within the specified symptom-onset or last-known-well window.
Not for mobile diagnostic use, isolated subarachnoid hemorrhage, recent neurosurgery or endovascular neurointervention within 6 weeks, or prior intracranial hemorrhage within 4 weeks. Not suitable for scan data with tumors or abscesses, coils, shunts, embolization, movement artifacts, or specified intracranial vascular pathologies. Results do not replace full patient evaluation or diagnosis.
Retrospective standalone testing used 341 non-contrast CT studies from 30 U.S. hospitals and clinics; all cases were processed. Ground truth used experienced U.S. board-certified neuroradiologists. The confusion matrix was TP 149, TN 159, FP 15, FN 18, yielding overall sensitivity (positive percentage agreement) 89.22% and specificity (negative percentage agreement) 91.37%. Subgroup endpoints include ICH subtype, gender, age, slice thickness, site, and hemorrhage volume. A separate time-to-notification analysis reported 50-126 seconds; the FDA primary acceptance criterion was 80% sensitivity and specificity.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
Retrospective standalone testing used 341 non-contrast CT studies from 30 U.S. hospitals and clinics; all cases were processed. Ground truth used experienced U.S. board-certified neuroradiologists. The confusion matrix was TP 149, TN 159, FP 15, FN 18, yielding overall sensitivity (positive percentage agreement) 89.22% and specificity (negative percentage agreement) 91.37%. Subgroup endpoints include ICH subtype, gender, age, slice thickness, site, and hemorrhage volume. A separate time-to-notification analysis reported 50-126 seconds; the FDA primary acceptance criterion was 80% sensitivity and specificity.
Acute intracranial-hemorrhage standalone sensitivity (positive percentage agreement, TP/[TP+FN]) in 341 adult non-contrast brain CT studies: 89.22% (TP 149, FN 18); the FDA text does not state an overall confidence interval for this value.
FDA source
Exact FDA submission
Checked 2026-09-09
The FDA endpoint is bounded to acute adult NCCT ICH notification and is distinct from the 80% prespecified acceptance criterion, subtype sensitivity, and 50-126-second notification interval.
Acute intracranial-hemorrhage standalone specificity (negative percentage agreement, TN/[TN+FP]) in 341 adult non-contrast brain CT studies: 91.37% (TN 159, FP 15); the FDA text does not state an overall confidence interval for this value.
FDA source
Exact FDA submission
Checked 2026-09-09
The FDA endpoint is bounded to acute adult NCCT ICH notification and is distinct from the 80% prespecified acceptance criterion and subgroup endpoints.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
Brainomix 360 Triage ICH regulatory performance study summary
DesignStand-Alone Performance
PopulationAdult
Scopeexact submission
Tested versionExact product version not reported; regulatory study summarized for FDA submission K231195
Samplen=341
Sites30
IndependenceIndependence not established
K231195
ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K231195. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: Non-contrast brain CT images from adult acute-care patients within 24 hours of acute-symptom onset or since last known well when unclear; the FDA packet states validation and intended use on GE and Philips scanners.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: The FDA packet describes a DICOM-compliant package on a standard physical or virtual server within a hospital-network workflow, with mobile and web notification channels; exact current PACS/RIS/EHR interfaces, versions, and local compatibility are not established.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: The exact FDA package describes Brainomix 360 Triage ICH as a DICOM-compliant software package running on an off-the-shelf physical or virtual server installed within a hospital network, with notification through a mobile application and web user interface. Current hosting, data flow, and commercial configuration require vendor confirmation.
Scope: Exact FDA submission. Packet wording: "Brainomix 360 Triage ICH is a radiological computer aided triage and notification software package compliant with the DICOM standard and running on an off-the-shelf physical or virtual server." … "Both proposed and predicate devices run on standard physical and/or virtual servers which are installed within a hospital network". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Confirm processing location, queue ownership, exclusions and exact AI build.
Source context, not route validation: Priority notification or a suspected-hemorrhage flag to clinicians, accessible through a web interface and mobile application, with compressed preview images for informational notification only; notified clinicians must view non-compressed images on a diagnostic viewer.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: Priority notification or a suspected-hemorrhage flag to clinicians, accessible through a web interface and mobile application, with compressed preview images for informational notification only; notified clinicians must view non-compressed images on a diagnostic viewer.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The exact FDA package describes Brainomix 360 Triage ICH as a DICOM-compliant software package running on an off-the-shelf physical or virtual server installed within a hospital network, with notification through a mobile application and web user interface. Current hosting, data flow, and commercial configuration require vendor confirmation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "Brainomix 360 Triage ICH is a radiological computer aided triage and notification software package compliant with the DICOM standard and running on an off-the-shelf physical or virtual server." … "Both proposed and predicate devices run on standard physical and/or virtual servers which are installed within a hospital network". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
The FDA packet describes a DICOM-compliant package on a standard physical or virtual server within a hospital-network workflow, with mobile and web notification channels; exact current PACS/RIS/EHR interfaces, versions, and local compatibility are not established.
Brainomix's current official FAQ describes ISO 27001, GDPR, and DPA controls for the current Brainomix 360 family; this does not establish certificate scope, expiry, deployed configuration, or exact K243294 security controls.
Product family
Checked 2026-10-25
Obtain current certificate scope, data-processing terms, hosting region, encryption, identity/access, audit, retention, and incident-response evidence for the deployed release.
ACR AI Central provides an exact-submission model card for Brainomix 360 Triage ICH; FDA labeling remains controlling for clinical use, limitations, and performance.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-20Last searched
26Fields reviewed
10Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, vendor documentation, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not verified - checked 2026-09-09 - Exact FDA submission
No public price or quote for the exact K231195 configuration was established in this review.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-09-09 - Exact FDA submission
No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-09-09 - Exact FDA submission
Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
Monitoring: Not verified - checked 2026-09-09 - Exact FDA submission
Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.
Authorized purpose: Methinks CTA Stroke analyzes acute-setting brain CT angiography in adults over 21 with suspected stroke for suspected large-vessel occlusion in the terminal ICA, MCA-M1, or MCA-M2 and sends PACS and/or specialist notifications in parallel to standard care; previews are informational and not diagnostic.
Authorized purpose: Rapid CTA 360 analyzes adult head CTA DICOM images to flag suspected large- and medium-vessel occlusion in specified intracranial and vertebral segments and notify trained clinicians for workflow triage; notifications are informational and not diagnostic.
Authorized purpose: Methinks NCCT Stroke analyzes adult non-contrast head CT to flag suspected intracranial hemorrhage and suspected large-vessel occlusion of the ICA, MCA-M1, or MCA-M2 for parallel workflow triage via PACS and/or notifications; previews are informational, not diagnostic, and a negative notification does not rule out LVO or replace CTA/standard care.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.